Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Payables (2019 - 2026)

Biodesix filings provide 8 years of Payables readings, the most recent being $3.7 million for Q1 2026.

  • On a quarterly basis, Payables rose 24.13% to $3.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.7 million, a 24.13% increase, with the full-year FY2025 number at $3.1 million, up 39.32% from a year prior.
  • Payables hit $3.7 million in Q1 2026 for Biodesix, up from $3.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $16.4 million in Q3 2022 to a low of $1.6 million in Q1 2023.
  • Median Payables over the past 5 years was $3.0 million (2023), compared with a mean of $4.2 million.
  • Biggest five-year swings in Payables: soared 914.44% in 2022 and later tumbled 82.03% in 2023.
  • Biodesix's Payables stood at $1.7 million in 2022, then skyrocketed by 71.86% to $3.0 million in 2023, then fell by 25.67% to $2.2 million in 2024, then soared by 39.32% to $3.1 million in 2025, then increased by 18.37% to $3.7 million in 2026.
  • The last three reported values for Payables were $3.7 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025) per Business Quant data.